Eli Lilly and Co (NYSE:LLY) and partner Boehringer Ingelheim announced that the European Commission has approved their sodium glucose co-transporter-2 (SGLT2) inhibitor, Jardiance (empagliflozin). Jardiance (10 mg and 25 mg once daily tablets) is approved as an adjunct to diet and exercise for improving glycemic control in adults suffering from type II diabetes. Eli Lilly intends to launch Jardiance in the EU in the third quarter of 2014. Eli Lilly and Co (NYSE:LLY) net profit margin is 17.40% and weekly performance is 1.77%. On last trading day company shares ended up $59.70. Analysts mean target price for the company is $60.88. Eli Lilly and Co (NYSE:LLY) distance from 50-day simple moving average (SMA50) is 1.85%.
Sanofi acquires the exclusive rights to apply for approval of Cialis OTC in the United States, Europe, Canada and Australia. Sanofi also holds exclusive rights to market Cialis OTC following Sanofi’s receipt of all necessary regulatory approvals. If approved, Sanofi anticipates providing Cialis OTC after expiration of certain patents. Terms of the licensing agreement were not disclosed. Sanofi SA (ADR) (NYSE:SNY) shares fell -0.36% in last trading session and ended the day on $52.99. SNY Gross Margin is 67.20% and its return on assets is 3.10%. Sanofi SA (ADR) (NYSE:SNY) quarterly performance is 6.73%.
On 27 MAY Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that the company is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the Grand Hyatt in New York, New York. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved down -0.79% in last trading session and was closed at $6.26, while trading in range of $6.22 – $6.41. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is 7.01%.
Merck & Co., Inc. (NYSE:MRK) declared that its Board of Directors has approved a quarterly dividend for the company’s stockholders. The quarterly dividend payable is of $0.44 on every share of Merck’s ordinary stock. The dividend will be payable for the third quarter of 2014. The payment will be made to the stockholders on July 8, 2014 as per the record at the business closing on June 16, 2014. Merck & Co., Inc. (NYSE:MRK) ended the last trading day at $56.40. Company weekly volatility is calculated as 0.95% and price to cash ratio as 9.43. Merck & Co., Inc. (NYSE:MRK) showed a positive weekly performance of 0.71%.
On 22 MAY Roche Holding Ltd. (ADR) (OTCMKTS: RHHBY) to be scrutinized by Chinese authorities, who are investigating foreign businesses for possible economic crimes conducted in the country. The Swiss drug maker confirmed that a unit of Chinese anti-trust regulators visited its Hangzhou operations in Eastern China yesterday. It further said that it would cooperate with the authorities as far as the investigations are concerned. Management did not say anything about the purpose of the visit. Roche Holding Ltd. (ADR) (OTCMKTS: RHHBY) on last trading day company shares ended up $36.84.
Leave a Reply